Ionis Pharmaceuticals

IONS

Market cap $13.4B

Ionis Pharmaceuticals, Inc. ( IONS ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Good afternoon. It's hard to check sometimes.

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx™ drug delivery system.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of DAWNZERA™ (donidalorsen) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The positive opinion is now referred to the European Commission (EC) for an.

Ionis Pharmaceuticals, Inc. ( IONS ) Stifel 2025 Healthcare Conference November 13, 2025 8:00 AM EST Company Participants Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Elizabeth L. Hougen - Executive VP of Finance & CFO Conference Call Participants Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Paul Matteis Stifel, Nicolaus & Company, Incorporated, Research Division Good morning.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $700.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2030 (the “notes”) in a private placement (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ionis also granted the initial purchasers of the notes an option to purchase, within the 13-day period beginning on, and inclu.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 Jefferies Global Healthcare Conference on Tuesday, November 18, 2025 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. Rep.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $700.0 million aggregate principal amount of Convertible Senior Notes due 2030 (the “notes”) in a private placement (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ionis also intends to grant the initial purchasers of the notes an option.

Ionis Pharmaceuticals, Inc. ( IONS ) Discusses Detailed Phase III Results for Olezarsen in Severe Hypertriglyceridemia November 8, 2025 3:00 PM EST Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Sotirios Tsimikas - Senior Vice President of Global Cardiovascular Development Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Conference Call Participants Jay Olson - Oppenheimer & Co. Inc., Research Division Mani Foroohar - Leerink Partners LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Debjit Chattopadhyay - Guggenheim Securities, LLC, Research Division Denis Reznik - Raymond James & Associates, Inc., Research Division Zaki Molvi - Jefferies LLC, Research Division Tommie Reerink - Goldman Sachs Group, Inc., Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Luca Issi - RBC Capital Markets, Research Division Myles Minter - William Blair & Company L.L.C.

Ionis Pharmaceuticals maintains a Buy rating as its transformation to a commercial company accelerates, driven by wholly-owned product launches and revenue growth. Q3 results highlight a revenue shift toward Ionis-owned drugs, with Tryngolza outperforming and Dawnzera launching as a differentiated HAE prophylactic. Olezarsen's strong Phase 3 data in sHTG positions IONS for a blockbuster opportunity, despite market competition and ongoing patent litigation with Arrowhead.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Sunday shared results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG), a condition characterized by dangerously high triglyceride (fat) levels.